FORM 20-F/A

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

           [_] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                                       OR

                [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                   For the fiscal year ended December 31, 2004

                                       OR

             [_] TRANSITION REPORT PURSUANT TO SECTION 12(b) OR (g)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
           for the transition period from ____________ to ____________

                           Commission File No. 0-17788

                          HEALTHCARE TECHNOLOGIES LTD.
              (Exact name of registrant as specified in its charter
               and translation of Registrant's Name into English)

                                     ISRAEL
                 (Jurisdiction of incorporation or organization)

                         BEIT AMARGAD, 32 SHAHAM STREET,
                   KIRYAT MATALON, PETACH TIKVA, ISRAEL, 49170
                    (Address of principal executive offices)

              Securities registered or to be registered pursuant to
                            Section 12(b) of the Act:
                                      None

 Securities registered or to be registered pursuant to Section 12(g) of the Act:

                  ORDINARY SHARES, NIS 0.04 PAR VALUE PER SHARE
                                (Title of Class)

          Securities for which there is a reporting obligation pursuant
                          to Section 15(d) of the Act:
                                      None

     Indicate the number of outstanding shares of each of the issuer's classes
of capital or common stock as of the close of the period covered by the annual
report:

<PAGE>


     As of December 31, 2004, the registrant had outstanding 7,702,832 Ordinary
Shares, NIS 0.04 nominal value per share. Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days:


                               Yes [X]     No [_]

     Indicate by check mark which financial statement item the Registrant has
elected to follow:

                          Item 17. [_]     Item 18. [X]



                                EXPLANATORY NOTE

     The Registrant filed its Annual Report on Form 20-F for the fiscal year
ended December 31, 2004 with the Securities and Exchange Commission on June 29,
2005. This Amendment to the Form 20-F is being filed to file certain exhibits
that were inadvertently omitted from the original filing.



<PAGE>


ITEM 19. FINANCIAL STATEMENTS AND EXHIBITS

     (B)  EXHIBITS

EXH.   INCORP.
NO.    BY REF. TO

1.1    1.1(8)   Memorandum of Association of the Registrant, as amended.

1.2    (16)     Articles of Association, restated to include all amendments in
                effect as of the date of this Report

2.1    2.1(1)   Debenture Purchase Agreement, dated as of May 14, 1991, among
                Healthcare, Rosebud, Evergreen-Canada Israel Investment and
                Company Ltd. et. al.

4.1    2.3(1)   Agreement dated February 21, 1991 between Savyon and New
                Horizons Diagnostic Corp.

4.2    2.4(1)   Agreement dated August 1, 1986 between Diatech Ltd. and Diamotek
                Ltd.

4.3    2.5(1)   Agreement dated February 22, 1987 between Diatech Ltd. and
                Yissum University.

4.4    2.6(1)   Agreement dated September 9, 1987 between Diatech Ltd. and Ramot
                University Authority for Applied Research & Industrial
                Development Ltd.

4.5    2.7(1)   Agreement dated July 15, 1989 between Diatech Ltd. and Yissum
                University.

4.6    2.8(1)   Agreement dated January 1, 1991 between Diatech Ltd. and Yeda.

4.7    2.9(1)   Distributorship Agreement between Savyon and Toshin, dated March
                3, 1986.

4.8    2.11(4)  Lease Agreement for Savyon's Facilities in Ashdod, Israel, dated
                March 29, 1993.

4.9    2.13(4)  Agreement between the Company and Savyon dated October 10, 1994.

4.10   2.15(6)  Agreement dated January 23, 1995 between the Company, Eriphyle
                Trading Ltd. and Gamida-Gen Marketing Ltd., for the acquisition
                by the Company of shares of Gamida-Gen Marketing Limited
                (Gamidor).

<PAGE>


4.11   2.17(7)  Agreement dated April 10, 1997 between the Company, Gamida for
                Life BV, Yacob Ofer, Gamida-Gen Marketing Ltd. and Gamidor
                Diagnostics (1984) Ltd., for the acquisition by the Company of
                ordinary shares of Gamida-Gen Marketing Ltd.

4.12   2.19(9)  Asset Purchase Agreement dated October 7, 1998 between Gamidor
                Limited (Gamidor UK) and Gamidor Diagnostics UK.

4.13   2.20(9)  Agreement dated December 23, 1998 between the Company, Gamida
                Trading Ltd., Gamida for Life BV and Gamidor Limited (Gamidor
                UK).

4.14   2.21(9)  Heads of Agreement dated October 1, 1998 between Gamidor
                Diagnostics (1994) Ltd. and the principal shareholder in Yaron
                Chemicals Ltd.

4.15   2.22(9)  Agreement dated February 7, 1999 between Healthcare Technologies
                Ltd., Hadasit Medical Research Services & Development Limited
                and others.

4.16   2.23(9)  Agreement between Luly Gurevich and Entity as adopted by
                Healthcare Technologies Ltd. in June 1999.

4.17   (16)     The Company's amended year 2000 Incentive Share Option Plan.

4.18   2.25(11) Share Purchase Agreement dated August 21, 2000, by and between
                Healthcare Technologies Ltd., Glycodata Ltd., Mr. Ofer Markman,
                Mr. Yeshayahu Yakir and certain investors, including Form of
                Convertible Debenture attached as Exhibit B thereto.

4.19   2.26(11) Share Purchase Agreement dated October 2, 2000 between
                Healthcare Technologies Ltd., Gamida For Life BV (and other
                shareholders of GamidaGen Ltd.) and GamidaGen Ltd.

4.20   2.27(11) Assignment and Transfer Agreement dated December 1, 2000 between
                Healthcare Technologies Ltd. and Savyon Diagnostics Ltd.

4.21   2.28(11) Asset Transfer and Assignment Agreement dated December 30, 2000
                between Diatech Diagnostics Inc, Diatech Diagnostics Ltd. and
                Savyon Diagnostics Ltd.

<PAGE>


4.22   2.29(11) Share Sale and Assignment Agreement dated December 31, 2000
                between Diatech Diagnostics Inc, Diatech Diagnostics Ltd. and
                Healthcare Technologies Ltd.

4.23   2.30(11) Agreement dated January 21, 2001 between Healthcare Technologies
                Ltd and Savyon Diagnostics Ltd.

4.24   2.31(12) Share Exchange Agreement dated April 29, 2002 between Procognia
                Ltd., Glycodata Ltd., Healthcare Technologies Ltd. and the other
                shareholders of Glycodata Ltd.

4.25   2.32(12) Subscription and Shareholders' Agreement relating to Procognia
                Ltd. dated April 29, 2002 between certain investors, executives
                and additional subscribers, Healthcare Technologies Ltd.,
                Procognia Ltd. and Glycodata Ltd.

4.26   99.1(13) Distribution Agreement between Dade Behring Marburg GmbH and
                Gamidor Diagnostics

4.27   99.2(13) Distribution Agreement between Amersham Pharmacia Biotech AB and
                Danyel Biotech Ltd.

4.28   99.3(13) Deal Structure Document for Savyon 2003 Transaction.

4.29   10(14)   Agreement between Biodiagnostic (Savyon) and Advance Products
                (B.G. Negev Technologies and Applications) Ltd. dated October
                31, 1983.

4.30   4.30     Agreement dated October 26, 1994 with the Washington Research
                Foundation.

4.31   (14)     Assignment Agreement Amersham - dated August 2, 2001.

4.32   (16)     Term Sheet for ImmvaRx transaction.

4.33   (17)     Audit Committee Charter.

4.34   (17)     Agreement for the sale of the Company's shares in Procognia to
                Gamida.

8.     99.5     Subsidiaries of the Registrant.

<PAGE>


11     (17)     Code of Ethics

12.1   (15)     Certification of Chief Executive Officer pursuant to 18 U.S.C.
                Section 1350 as adopted pursuant to Section 906 of the
                Sarbanes-Oxley Act Of 2002.

12.2   (15)     Certification of Chief Financial Officer pursuant to 18 U.S.C.
                Section 1350 as adopted pursuant to Section 906 of the
                Sarbanes-Oxley Act Of 2002.

12.3   (15)     Certification of Chief Executive Officer pursuant to Rule
                13a-14(a) of the Securities Exchange Act of 1934, as amended.

12.4   (15)     Certification of Chief Financial Officer pursuant to Rule
                13a-14(a) of the Securities Exchange Act of 1934, as amended.

23     (17)     Consent of Kost Forer& Gabbay.



                ----------

       (1)      Incorporated  by reference to the  Registrant's  Registration
                Statement on Form F-1 (File No. 44811)

       (2)      Incorporated  by reference to the  Registrant's  Registration
                Statement on Form F-1 (File No. 33-22868)

       (3)      Incorporated  by reference to the  Registrant's  Registration
                Statement on Form F-1 (File No. 33-54190)

       (4)      Incorporated  by reference to the  Registrant's  Registration
                Statement on Form F-2 (File No. 33-85144)

       (5)      Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1994.

       (6)      Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1995.

       (7)      Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1996.

       (8)      Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1997.

       (9)      Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1998.

       (10)     Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 1999.

       (11)     Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 2000.

       (12)     Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the fiscal year ended December 31, 2001, as
                amended.

<PAGE>


       (13)     Incorporated  by reference to Registrant's  Registration
                Statement on form F-3 (SEC File No. 333-99601).

       (14)     Incorporated  by reference to Registrant's  Registration
                Statement on Form F-3 (SEC File No. 33-22868).

       (15)     Filed herewith.

       (16)     Incorporated  by reference to the  Registrant's  Annual Report
                on Form 20-F for the Fiscal year ended December 31, 2003.

       (17)     Incorporated  by reference to the  Registrant's  Annual  Report
                on Form 2-F for the fiscal year ended December 31, 2004.




<PAGE>


                                   SIGNATURES


     The registrant hereby certifies that it meets all of the requirements for
filing on Form 20-F and that it has duly caused and authorized the undersigned
to sign this annual report on its behalf.

                                                    HEALTHCARE TECHNOLOGIES LTD.


                                                    By: /s/ Moshe Reuveni
                                                    ---------------------
                                                    Moshe Reuveni
                                                    Chief Financial Officer



Date:  July 1, 2005